XML 35 R17.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information

Note 8 – Segment Information

 

The Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE®), and Tetra-specific Killer Engager (Dual Targeting TriKE®) platforms. The measure of segment assets is reported on the balance sheet as total assets.

 

The Company’s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance.

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:

 

   2025   2024   2025   2024 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2025   2024   2025   2024 
Research and development  $363,000   $1,805,000   $1,462,000   $2,561,000 
Salaries   351,000    287,000    632,000    765,000 
Insurance   61,000    76,000    121,000    152,000 
Stock-based compensation   4,000    120,000    7,000    222,000 
Operating expenses   734,000    1,619,000    1,223,000    3,297,000 
Other income   (80,000)   (197,000)   (1,236,000)   (1,021,000)
Net loss  $1,433,000   $3,710,000   $2,209,000   $5,976,000